Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: Comparison with OctreoScan® in two cases

0Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs. © 2012 Cossetti et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Cossetti, R. J. D., Bezerra, R. O. F., Gumz, B., Telles, A., & Costa, F. P. (2012). Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: Comparison with OctreoScan® in two cases. World Journal of Surgical Oncology, 10. https://doi.org/10.1186/1477-7819-10-82

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free